US 20260345734 A1: Use of C-type natriuretic peptide variants to treat skeletal dysplasia

Case summary

The case is for application US 19/407,862. Its prior art date is 2015-07-30, a date entered by hand. It has 35 claims, as published, 2026-11-05. Claims 1, 16 and 23 are independent. Claims 5, 8 to 15, 18, 21, 22, 26, 29 and 30 are cancelled. The claims have 21 features, by kind: SEQ ID (21). The listing, “us20260345734a1-listing.xml”, holds 7 sequences: 7 protein sequences of 37 to 39 residues. Organisms, with how many sequences name each: Homo sapiens (7). The listing is the copy in a weekly full-text file, so it was not checked against WIPO ST.26. The claims recite SEQ ID NOs: 1-7. SEQ ID NO: 1 (protein, 37 residues, Homo sapiens) is recited in claims 1, 16 and 23, and the description cites it in 2 paragraphs. SEQ ID NO: 2 (protein, 38 residues, Homo sapiens) is recited in claims 1, 16 and 23, and the description cites it in 2 paragraphs. SEQ ID NO: 3 (protein, 38 residues, Homo sapiens) is recited in claims 1, 16 and 23, and the description cites it in 2 paragraphs. SEQ ID NO: 4 (protein, 38 residues, Homo sapiens) is recited in claims 1, 16 and 23, and the description cites it in 2 paragraphs. SEQ ID NO: 5 (protein, 39 residues, Homo sapiens) is recited in claims 1, 16 and 23, and the description cites it in 3 paragraphs. Plan version 1, locked on 2026-11-24, has 1 group: SEQ ID NOs: 1-7 on Patent proteins and Swiss-Prot (2 searches). Every kept feature has a search. Plan version 1 ran: 2 of 2 search jobs done.

Filled in from template conductbiology.summaries.template.case.v1 b65b47e0. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.

Case	US 20260345734 A1: Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Case ID	`8fca4efc-1306-400b-af10-e7dce023e84f`
Started	2026-11-24 00:15 UTC by ConductScience
Application	US 19/407,862
Prior art date	2015-07-30 (entered by hand)
Searches	2: 2 run from the plan, 0 added
Chosen results	5 publications and 0 matches kept
Notes	0
Case log	60 events; every event checks out
Last log event	Event 60, 2026-11-24 00:18 UTC
Last event SHA-256	`0b439b3ae45e9d5f989ffd2b7371eb5ea6bfd7f19142ff3d9cf726a000c30630`

Each search below names its record fingerprint: the SHA-256 that Sequences computed over the search record when the search finished. Opened in Sequences, the search shows the same value as recordSha256 under Search record. Any change to the record would change it.

Claims and plan

Claims	35 claims from US 20260345734 A1, imported 2026-11-24 00:15 UTC

Claims SHA-256	`7548c2b76b74e04ab91a1b2ae7fd128a877af233bc9d268109214430d7cd7efa`
Claim set	Set 1, as published, 2026-11-05, from US 20260345734 A1, publication XML
Features	21: 21 accepted
Plan	Version 1, locked 2026-11-24 00:15 UTC, 2 searches
Plan SHA-256	`4b671f835c229b6ab957ecdcb206acfeceec6fbdf5e69aa8353ed754d0c96e81`
Plan follows	Set 1, as published, 2026-11-05, from US 20260345734 A1, publication XML, the current set
Its claims SHA-256	`7548c2b76b74e04ab91a1b2ae7fd128a877af233bc9d268109214430d7cd7efa`

The plan's searches

Plan version 1, locked 2026-11-24 00:15 UTC by ConductScience. Plan SHA-256 4b671f835c229b6ab957ecdcb206acfeceec6fbdf5e69aa8353ed754d0c96e81. Each search runs as written here.

The plan follows set 1, as published, 2026-11-05, from US 20260345734 A1, publication XML. Claims SHA-256 7548c2b76b74e04ab91a1b2ae7fd128a877af233bc9d268109214430d7cd7efa.

Search	Query	Method	Set	Thresholds	Reason
P1	SEQ ID NOs: 1 to 7 from the listing	Automatic	Patent proteins, snapshot 2026-11-13-5e447c75c43f	Published before 2015-07-30	SEQ ID NOs: 1 to 7, in claims 1, 16 and 23: as written.
P2	SEQ ID NOs: 1 to 7 from the listing	Automatic	Swiss-Prot, snapshot 2026-11-10-37cac4ca8f21	Published before 2015-07-30	SEQ ID NOs: 1 to 7, in claims 1, 16 and 23: as written.

Features no search covered

Every kept feature had a search when this version was locked.

Notes

This case has no notes.

Searches

#	Search	In the case	Finished (UTC)	Matches	Kept
1	US 20260345734 A1: Use of C-type natriuretic peptide variants to treat skeletal dysplasia, plan 1 P1: SEQ ID NO: 1 to 7	Plan 1, P1	2026-11-24 00:16	25,117	5
2	US 20260345734 A1: Use of C-type natriuretic peptide variants to treat skeletal dysplasia, plan 1 P2: SEQ ID NO: 1 to 7	Plan 1, P2	2026-11-24 00:16	9,171	0

By applicant

The publications a reviewer kept, and the publications that hold each kept match, by the first applicant each publication names. Spellings that differ only in case, accents, punctuation or an ending such as Inc or GmbH share a row, as do names joined in the Applicants tab, with the joins in force when this report was made. Rows go by earliest date, then name, with Applicant not given last.

Applicant	Publications	Earliest	Searches
Daniel J. Wendt	US 20100297021-A1, 2010-11-25	2010-11-25	1
Biomarin Pharmaceutical Inc.	US 8198242-B2, 2012-06-12 US 8598121-B2, 2013-12-03	2012-06-12	1
Philippe Crine	US 20120164142-A1, 2012-06-28	2012-06-28	1
Vanderbilt University	US 20130323244-A1, 2013-12-05	2013-12-05	1

Summaries

Sequences filled in each summary below from a fixed template, with facts it read from this case. The examiner accepted each one as written, or edited it into their own words, and each row says which. Summaries the examiner rejected are not printed. The case log records every decision.

The results

The case's searches found 6,165 references. 192 of them meet the threshold of a claim feature. 4,297 of them were published before the prior art date, 2015-07-30. 870 more were filed before that date and published later. 1 of them has no publication date. The top references: US 20100297021-A1 (rank 1, meets F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, F14, F15, F16, F17, F18, F19, F20 and F21); WO 2009067639-A1 (rank 2, meets F7, F14 and F21); EP 2432489-A2 (rank 3, meets F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, F14, F15, F16, F17, F18, F19, F20 and F21); US 8198242-B2 (rank 4, meets F1, F2, F3, F4, F5, F6, F7, F8, F9, F10, F11, F12, F13, F14, F15, F16, F17, F18, F19, F20 and F21); US 20100331256-A1 (rank 5, meets F7, F14 and F21). Every claim feature has a reference that meets its threshold. They come from searches 1 and 2 from the plan.

Filled in from template conductbiology.summaries.template.results.v1 91ed1f45. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.

What the description says about each claimed SEQ ID NO

SEQ ID NO	Summary	Filled in, then accepted by the examiner
SEQ ID NO: 1	SEQ ID NO: 1 is recited in claims 1, 16 and 23. Claim 1 recites “SEQ ID NO: 1” (threshold as written: identical over the full query). Claim 16 recites “SEQ ID NO: 1” (threshold as written: identical over the full query). Claim 23 recites “SEQ ID NO: 1” (threshold as written: identical over the full query). The description cites it in 2 paragraphs. Paragraph p-0022: “[CNP-37(M32N); SEQ ID NO: 1]” Paragraph p-0080: “CNP-37(M32N); SEQ ID NO: 1]”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.
SEQ ID NO: 2	SEQ ID NO: 2 is recited in claims 1, 16 and 23. Claim 1 recites “SEQ ID NO: 2” (threshold as written: identical over the full query). Claim 16 recites “SEQ ID NO: 2” (threshold as written: identical over the full query). Claim 23 recites “SEQ ID NO: 2” (threshold as written: identical over the full query). The description cites it in 2 paragraphs. Paragraph p-0022: “(Met-CNP-37; SEQ ID NO: 2)” Paragraph p-0080: “(Met-CNP-37; SEQ ID NO: 2)”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.

SEQ ID NO	Summary	Filled in, then accepted by the examiner
SEQ ID NO: 3	SEQ ID NO: 3 is recited in claims 1, 16 and 23. Claim 1 recites “SEQ ID NO: 3” (threshold as written: identical over the full query). Claim 16 recites “SEQ ID NO: 3” (threshold as written: identical over the full query). Claim 23 recites “SEQ ID NO: 3” (threshold as written: identical over the full query). The description cites it in 2 paragraphs. Paragraph p-0022: “(Pro-CNP-37; SEQ ID NO: 3)” Paragraph p-0080: “(Pro-CNP-37; SEQ ID NO: 3)”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.
SEQ ID NO: 4	SEQ ID NO: 4 is recited in claims 1, 16 and 23. Claim 1 recites “SEQ ID NO: 4” (threshold as written: identical over the full query). Claim 16 recites “SEQ ID NO: 4” (threshold as written: identical over the full query). Claim 23 recites “SEQ ID NO: 4” (threshold as written: identical over the full query). The description cites it in 2 paragraphs. Paragraph p-0022: “[Gly-CNP-37 (M32N); SEQ ID NO: 4]” Paragraph p-0080: “[Gly-CNP-37 (M32N); SEQ ID NO: 4]”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.
SEQ ID NO: 5	SEQ ID NO: 5 is recited in claims 1, 16 and 23. Claim 1 recites “SEQ ID NO: 5” (threshold as written: identical over the full query). Claim 16 recites “SEQ ID NO: 5” (threshold as written: identical over the full query). Claim 23 recites “SEQ ID NO: 5” (threshold as written: identical over the full query). The description cites it in 3 paragraphs. Paragraph p-0022: “(Pro-Gly-CNP-37; SEQ ID NO: 5)” Paragraph p-0080: “(Pro-Gly-CNP-37; SEQ ID NO: 5)” Paragraph [0147]: “Once baseline levels for growth velocity and body proportionality ratios were obtained, a formulation comprising a CNP variant peptide (specifically Pro-Gly-CNP-37; SEQ ID NO: 5) was then administered as a daily dose subcutaneously in one of the following daily dosing regimens: Cohort 1 (n=8): daily dose of 2.5 μg/kg of Pro-Gly-CNP-37 peptide, Cohort 2 (n=8), daily dose of 7.5 μg/kg of Pro-Gly-CNP-37 peptide; Cohort 3 (n=10), daily dose of 15.0 μg/kg of Pro-Gly-CNP-37 peptide.”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.
SEQ ID NO: 6	SEQ ID NO: 6 is recited in claims 1, 16 and 23. Claim 1 recites “SEQ ID NO: 6” (threshold as written: identical over the full query). Claim 16 recites “SEQ ID NO: 6” (threshold as written: identical over the full query). Claim 23 recites “SEQ ID NO: 6” (threshold as written: identical over the full query). The description cites it in 2 paragraphs. Paragraph p-0022: “(Met-Gly-CNP-37; SEQ ID NO: 6)” Paragraph p-0080: “(Met-Gly-CNP-37; SEQ ID NO: 6)”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.
SEQ ID NO: 7	SEQ ID NO: 7 is recited in claims 1, 16 and 23. Claim 1 recites “SEQ ID NO: 7” (threshold as written: identical over the full query). Claim 16 recites “SEQ ID NO: 7” (threshold as written: identical over the full query). Claim 23 recites “SEQ ID NO: 7” (threshold as written: identical over the full query). The description cites it in 2 paragraphs. Paragraph p-0022: “(Gly-CNP-37 or CNP-38: SEQ ID NO: 7)” Paragraph p-0080: “(Gly-CNP-37 or CNP-38: SEQ ID NO: 7)”	Filled in from template conductbiology.summaries.template.seqid.v1 8b59a799. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.

The searches

A search's summary describes what the search returned, before the examiner's marks. Each search's section below shows the marks.

Search	Summary	Filled in, then accepted by the examiner
Search 1	Search 1, “US 20260345734 A1: Use of C-type natriuretic peptide variants to treat skeletal dysplasia, plan 1 P1: SEQ ID NO: 1 to 7”, came from plan version 1, search P1. Method: Automatic (Smith-Waterman). Data searched: Public patent sequences and US applications: Patent proteins, snapshot 2026-11-13-5e447c75c43f, sources to 2026-11-13. Filters: published before 2015-07-30. Engine settings: tool: ssearch36; query: protein. It ran 7 queries and returned 25,117 hits. For feature F1 of claim 1 (“SEQ ID NO: 1”, threshold as written: identical over the full query), it found 2,460 references. The first 5 in rank order: US 20100297021-A1, EP 2432489-A2, US 8198242-B2, US 20120164142-A1 and JP 2012527244-A. US 20100297021-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2010-11-25, before the prior art date; Query Match 100.0%; E-value 9.30e-23. For feature F2 of claim 1 (“SEQ ID NO: 2”, threshold as written: identical over the full query), it found 2,683 references. The first 5 in rank order: US 20100297021-A1, EP 2432489-A2, US 8198242-B2, US 20120164142-A1 and JP 2012527244-A. US 20100297021-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2010-11-25, before the prior art date; Query Match 100.0%; E-value 1.20e-23. For feature F3 of claim 1 (“SEQ ID NO: 3”, threshold as written: identical over the full query), it found 2,706 references. The first 5 in rank order: US 20100297021-A1, EP 2432489-A2, US 8198242-B2, US 20120164142-A1 and JP 2012527244-A. US 20100297021-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2010-11-25, before the prior art date; Query Match 100.0%; E-value 6.70e-24. For feature F4 of claim 1 (“SEQ ID NO: 4”, threshold as written: identical over the full query), it found 2,658 references. The first 5 in rank order: US 20100297021-A1, EP 2432489-A2, US 8198242-B2, US 20120164142-A1 and JP 2012527244-A. US 20100297021-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2010-11-25, before the prior art date; Query Match 100.0%; E-value 1.80e-23. For feature F5 of claim 1 (“SEQ ID NO: 5”, threshold as written: identical over the full query), it found 3,412 references. The first 5 in rank order: US 20100297021-A1, EP 2432489-A2, US 8198242-B2, US 20120164142-A1 and JP 2012527244-A. US 20100297021-A1 ranks first. Rank keys, in order: meets as written (100.0% identity over the full query); coverage of the claimed region 100.0%; published 2010-11-25, before the prior art date; Query Match 100.0%; E-value 2.10e-24. It served more claim features than this summary has room for; the References step lists them all.	Filled in from template conductbiology.summaries.template.search.v1 6781e001. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.

Search	Summary	Filled in, then accepted by the examiner
Search 2	Search 2, “US 20260345734 A1: Use of C-type natriuretic peptide variants to treat skeletal dysplasia, plan 1 P2: SEQ ID NO: 1 to 7”, came from plan version 1, search P2. Method: Automatic (Smith-Waterman). Data searched: Public sequences: UniProt 2026_04 and ENA ESTs: Swiss-Prot, snapshot 2026-11-10-37cac4ca8f21, sources to 2026-11-10. Filters: published before 2015-07-30. Engine settings: tool: ssearch36; query: protein. It ran 7 queries and returned 9,171 hits. For feature F1 of claim 1 (“SEQ ID NO: 1”, threshold as written: identical over the full query), it found 1,583 references. The first 5 in rank order: P23582, P54229, Q54TU5, Q5SMC7 and P18104. P23582 ranks first. Rank keys, in order: not as written (97.3% identity over the full query); coverage of the claimed region 100.0%; published 1991, before the prior art date; Query Match 96.0%; E-value 7.80e-21. For feature F2 of claim 1 (“SEQ ID NO: 2”, threshold as written: identical over the full query), it found 1,416 references. The first 5 in rank order: P23582, P18104, P55207, P55206 and Q61839. P23582 ranks first. Rank keys, in order: not as written (97.4% identity over the full query); coverage of the claimed region 100.0%; published 1991, before the prior art date; Query Match 98.5%; E-value 4.10e-22. For feature F3 of claim 1 (“SEQ ID NO: 3”, threshold as written: identical over the full query), it found 1,532 references. The first 5 in rank order: F5CPE8, Q5SMC7, Q586F4, B3FIS4 and P19661. F5CPE8 ranks first. Rank keys, in order: not as written (47.4% identity over the full query); coverage of the claimed region 100.0%; published 2011, before the prior art date; Query Match 51.9%; E-value 4.10e-8. For feature F4 of claim 1 (“SEQ ID NO: 4”, threshold as written: identical over the full query), it found 1,825 references. The first 5 in rank order: P13204, O46541, A8EZ86, Q8TGG8 and Q9ZMJ6. P13204 ranks first. Rank keys, in order: not as written (52.6% identity over the full query); coverage of the claimed region 100.0%; published 1989, before the prior art date; Query Match 41.8%; E-value 5.40e-5. For feature F5 of claim 1 (“SEQ ID NO: 5”, threshold as written: identical over the full query), it found 1,718 references. The first 5 in rank order: A8YPR9, Q202B1, P13204, O46541 and Q86TI2. A8YPR9 ranks first. Rank keys, in order: not as written (41.0% identity over the full query); coverage of the claimed region 100.0%; published 2008, before the prior art date; Query Match 31.8%; E-value 8.20e-2. It served more claim features than this summary has room for; the References step lists them all.	Filled in from template conductbiology.summaries.template.search.v1 6781e001. Accepted by the examiner, ConductScience, 2026-11-24 00:18 UTC.

Claim charts

Each chart sets a claim's features against one reference. Fixed rules (claim charts 1.0.0) read each feature against the reference's best match in this case's searches: Met, Not met, or Not shown where the match does not show it. Where the examiner set an answer, the chart gives it with the rule's answer beside it and the examiner's note. The case log records every answer. In a patent's table, What the patent says quotes a US publication's own words on its matching SEQ ID NOs, word for word, with where each comes from, or says why there is no quote (fixed rules, quotes 1.0.0).

Claim 1 and US 20100297021-A1

Variants of C-Type Natriuretic Peptide. Published 2010-11-25, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 1 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 3,554 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 7,042 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 10,545 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 14,170 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 17,830 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 21,477 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].

Claim 1 and US 8198242-B2

Variants of C-type natriuretic peptide. Published 2012-06-12, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 1 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 3,554 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 7,042 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 10,545 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 14,170 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 17,830 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 21,477 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].

Claim 1 and US 20120164142-A1

COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF. Published 2012-06-28, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 1 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 3,554 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 7,042 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 10,545 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 14,170 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 17,830 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 21,477 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].

Claim 1 and US 8598121-B2

Variants of C-type natriuretic peptide. Published 2013-12-03, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 1 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 3,554 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 7,042 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 10,545 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 14,170 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 17,830 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 21,477 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].

Claim 1 and US 20130323244-A1

COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF. Published 2013-12-05, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 1 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 3,554 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 7,042 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 10,545 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 14,170 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 17,830 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 21,477 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].

Claim 16 and US 20100297021-A1

Variants of C-Type Natriuretic Peptide. Published 2010-11-25, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 1 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 3,554 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 7,042 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 10,545 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 14,170 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 17,830 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 21,477 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].

Claim 16 and US 8198242-B2

Variants of C-type natriuretic peptide. Published 2012-06-12, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 1 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 3,554 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 7,042 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 10,545 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 14,170 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 17,830 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 21,477 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].

Claim 16 and US 20120164142-A1

COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF. Published 2012-06-28, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 1 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 3,554 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 7,042 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 10,545 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 14,170 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 17,830 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 21,477 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].

Claim 16 and US 8598121-B2

Variants of C-type natriuretic peptide. Published 2013-12-03, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 1 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 3,554 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 7,042 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 10,545 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 14,170 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 17,830 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 21,477 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].

Claim 16 and US 20130323244-A1

COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF. Published 2013-12-05, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 1 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 3,554 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 7,042 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 10,545 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 14,170 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 17,830 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 21,477 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].

Claim 23 and US 20100297021-A1

Variants of C-Type Natriuretic Peptide. Published 2010-11-25, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 1 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 3,554 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 7,042 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 10,545 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 14,170 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 17,830 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 21,477 of search 1, US 20100297021-A1	The text after [0016]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0466]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in claim 42 and in paragraphs [0098] and [0103] and the text after [0016], the first 3 places of 10. SEQ ID NO: 2 is named in paragraph [0466], the text after [0016] and the text after [0374], the first 3 places of 8. SEQ ID NO: 3 is named in paragraphs [0466], [0467] and [0525].

Claim 23 and US 8198242-B2

Variants of C-type natriuretic peptide. Published 2012-06-12, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 1 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 3,554 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 7,042 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 10,545 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 14,170 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 17,830 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 21,477 of search 1, US 8198242-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0494]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0101] and [0106], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0388] and [0494], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0494], [0495] and [0525].

Claim 23 and US 20120164142-A1

COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF. Published 2012-06-28, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 1 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 3,554 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 7,042 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 10,545 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 14,170 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 17,830 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 21,477 of search 1, US 20120164142-A1	Paragraph [0146]: “FIG. 1 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0203]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 1, e.g., amino acids 24-28 of SEQ ID NO: 1, amino acids 28-32 of SEQ ID NO: 2, amino acids 27-32 of SEQ ID NO: 3, or amino acids 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0146] and [0203]. SEQ ID NO: 2 is named in paragraphs [0146] and [0203]. SEQ ID NO: 3 is named in paragraphs [0146] and [0203].

Claim 23 and US 8598121-B2

Variants of C-type natriuretic peptide. Published 2013-12-03, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 1 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 3,554 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 7,042 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 10,545 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 14,170 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 17,830 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 17, 19, 20, 21, 22, 33, 34, 35, 36, 37, 38, 39, 40 and 41, and 181 more. Source: Row 21,477 of search 1, US 8598121-B2	Paragraph [0017]: “(SEQ ID NO: 1) (N-terminus) Gly1-Leu2-Ser3-Lys4-Gly5-Cys6-Phe7-Gly8-Leu9-Lys10-Leu11-Asp12-Arg13-Ile14-Gly15-Ser16-Met17-Ser18-Gly19-Leu20-Gly21-Cys22.” Paragraph [0485]: “In an embodiment, the present disclosure optionally excludes the peptides of SEQ ID NOs 1-4 and 6-71 as specifically disclosed in U.S. Pat.” SEQ ID NO: 1 is named in paragraphs [0017], [0104] and [0110], the first 3 places of 10. SEQ ID NO: 2 is named in paragraphs [0017], [0378] and [0485], the first 3 places of 7. SEQ ID NO: 3 is named in paragraphs [0485], [0486] and [0512].

Claim 23 and US 20130323244-A1

COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF. Published 2013-12-05, before the prior art date. Kept in a search.

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 1	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 1 positions 1 to 37 align with positions 1 to 37 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 1 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 2	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 2 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 3,554 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 3	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 3 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 7,042 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 4	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 4 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 10,545 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 5	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 5 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 14,170 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].
SEQ ID NO: 6	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 6 positions 1 to 39 align with positions 1 to 39 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 17,830 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].

Claim feature	Answer	What the match shows	What the patent says
SEQ ID NO: 7	Met	Meets as written: 100.0% identity over the full query. SEQ ID NO: 7 positions 1 to 38 align with positions 1 to 38 of its sequence. Its SEQ ID NOs: 1, 2, 3, 4, 5, 6, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24, and 491 more. Source: Row 21,477 of search 1, US 20130323244-A1	Paragraph [0196]: “FIG. 12 is a multiple sequence alignment of human ANP (SEQ ID NO: 1), human urodilatin (SEQ ID NO: 2), human BNP (SEQ ID NO: 3), human CNP22 (SEQ ID NO: 4), and DNP (SEQ ID NO: 5).” Paragraph [0243]: “Exemplary C-terminal extensions are shown immediately C-terminal to the boxed region in FIG. 12, e.g., amino acid residues 24-28 of SEQ ID NO: 1, amino acid residues 28-32 of SEQ ID NO: 2, amino acid residues 27-32 of SEQ ID NO: 3, or amino acid residues 24-38 of SEQ ID NO: 5.” SEQ ID NO: 1 is named in paragraphs [0196] and [0243]. SEQ ID NO: 2 is named in paragraphs [0196] and [0243]. SEQ ID NO: 3 is named in paragraphs [0196] and [0243].

Search 1: US 20260345734 A1: Use of C-type natriuretic peptide variants to treat skeletal dysplasia, plan 1 P1: SEQ ID NO: 1 to 7

Search ID	`48438060-ef30-4424-a888-08251a2282e4`
In this case	Run from plan version 1, search P1, by ConductScience on 2026-11-24 00:15 UTC
Finished	2026-11-24 00:16 UTC
Data searched	Public patent sequences and US applications: Patent proteins (17,651,841 sequences, 2,420,942,521 letters)
Data version	Snapshot 2026-11-13-5e447c75c43f, set patent_prot, sources to 2026-11-13, no additions
Engine	FASTA 36.3.8i; Sequences search engine 0.21.0
Settings	engine: Automatic; tool: ssearch36; program: blastp; query: protein
Plan filters	The tables below show matches with published before 2015-07-30, as the plan set
Query fingerprint	`e3b44e3c8578b2eee4b1a2c357d145ec5ab45e87a802ee00fa220c0b2880d52c`
Record fingerprint	`60f60c02d8a7a4b4bef94126bd070f4a711ab5a154aa6ce3baa3bda34ffc26c2`

Smith-Waterman compares each query with every stored sequence. Each query returns up to 5,000 sequences, with the best alignment of each. FASTA36 fits its E-values to a sample of scores it draws the same way on every run, so the same search on the same snapshot returns the same rows. These results do not establish patentability.

Queries

Query	Length	Matches	Listed	Limit reached
SEQ_ID_NO_1	37		3,553	No
SEQ_ID_NO_2	38		3,488	No
SEQ_ID_NO_3	38		3,503	No
SEQ_ID_NO_4	38		3,625	No
SEQ_ID_NO_5	39		3,660	No
SEQ_ID_NO_6	39		3,647	No
SEQ_ID_NO_7	38		3,641	No

```
>SEQ_ID_NO_1  (37 letters)
      1  QEHPNARKYK GANKKGLSKG CFGLKLDRIG SNSGLGC

>SEQ_ID_NO_2  (38 letters)
      1  MQEHPNARKY KGANKKGLSK GCFGLKLDRI GSMSGLGC

>SEQ_ID_NO_3  (38 letters)
      1  PQEHPNARKY KGANKKGLSK GCFGLKLDRI GSMSGLGC

>SEQ_ID_NO_4  (38 letters)
      1  GQEHPNARKY KGANKKGLSK GCFGLKLDRI GSNSGLGC

>SEQ_ID_NO_5  (39 letters)
      1  PGQEHPNARK YKGANKKGLS KGCFGLKLDR IGSMSGLGC

>SEQ_ID_NO_6  (39 letters)
      1  MGQEHPNARK YKGANKKGLS KGCFGLKLDR IGSMSGLGC

>SEQ_ID_NO_7  (38 letters)
      1  GQEHPNARKY KGANKKGLSK GCFGLKLDRI GSMSGLGC
```

Chosen publications

Publication	Published	Filed	Applicant	Title	Best query match	Reason
US 20100297021-A1	2010-11-25	2010-05-20, priority 2009-05-20	Daniel J. Wendt	Variants of C-Type Natriuretic Peptide	100%	
US 8198242-B2	2012-06-12	2010-05-20, priority 2009-05-20	Biomarin Pharmaceutical Inc.	Variants of C-type natriuretic peptide	100%	
US 20120164142-A1	2012-06-28	2011-12-23, priority 2010-12-27	Philippe Crine	COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	100%	
US 8598121-B2	2013-12-03	2012-05-08, priority 2009-05-20	Biomarin Pharmaceutical Inc.	Variants of C-type natriuretic peptide	100%	
US 20130323244-A1	2013-12-05	2013-05-21, priority 2012-05-21	Vanderbilt University	COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF	100%	

Why each chosen publication counts

The sentences a reviewer accepted, or edited into their own words, for each kept publication. Each draft stated one stored fact, and the case log keeps every draft and decision.

Publication	Why it counts	Sources
US 20100297021-A1	SEQ ID NO: 145 of US 20100297021-A1 matches SEQ ID NO: 5 of claims 1, 16 and 23 at 100% identity over 39 of 39 residues (Query Match 100%). Published 2010-11-25, before the prior art date of 2015-07-30.	Row 14,170 of this search; US 20100297021-A1: https://patents.google.com/patent/US20100297021A1
US 8198242-B2	SEQ ID NO: 145 of US 8198242-B2 matches SEQ ID NO: 5 of claims 1, 16 and 23 at 100% identity over 39 of 39 residues (Query Match 100%). Published 2012-06-12, before the prior art date of 2015-07-30.	Row 14,170 of this search; US 8198242-B2: https://patents.google.com/patent/US8198242B2
US 20120164142-A1	SEQ ID NO: 1047 of US 20120164142-A1 matches SEQ ID NO: 5 of claims 1, 16 and 23 at 100% identity over 39 of 39 residues (Query Match 100%). Published 2012-06-28, before the prior art date of 2015-07-30.	Row 14,170 of this search; US 20120164142-A1: https://patents.google.com/patent/US20120164142A1
US 8598121-B2	SEQ ID NO: 145 of US 8598121-B2 matches SEQ ID NO: 5 of claims 1, 16 and 23 at 100% identity over 39 of 39 residues (Query Match 100%). Published 2013-12-03, before the prior art date of 2015-07-30.	Row 14,170 of this search; US 8598121-B2: https://patents.google.com/patent/US8598121B2
US 20130323244-A1	SEQ ID NO: 1047 of US 20130323244-A1 matches SEQ ID NO: 5 of claims 1, 16 and 23 at 100% identity over 39 of 39 residues (Query Match 100%). Published 2013-12-05, before the prior art date of 2015-07-30.	Row 14,170 of this search; US 20130323244-A1: https://patents.google.com/patent/US20130323244A1

Top publications

The first 15 of 3,693 publications, by best query match.

Publication	Published	Filed	Applicant	Title	Best query match	Matches
WO 2009067639-A1	2009-05-28		BioMarin Pharmaceutical Inc. (US)	Variants of c-type natriuretic peptide	100%	658
US 20100297021-A1	2010-11-25	2010-05-20, priority 2009-05-20	Daniel J. Wendt	Variants of C-Type Natriuretic Peptide	100%	1,176
US 20100331256-A1	2010-12-30	2008-11-21, priority 2007-11-21	Dan J. Wendt	Variants of C-Type Natriuretic Peptides	100%	672
JP 2011504506-A	2011-02-10		BioMarin Pharmaceutical Inc	Variants of C-Type Natriuretic Peptide	100%	658
EP 2432489-A2	2012-03-28		BIOMARIN PHARM INC	VARIANTS OF C-TYPE NATRIURETIC PEPTIDE	100%	1,176
US 8198242-B2	2012-06-12	2010-05-20, priority 2009-05-20	Biomarin Pharmaceutical Inc.	Variants of C-type natriuretic peptide	100%	1,176
US 20120164142-A1	2012-06-28	2011-12-23, priority 2010-12-27	Philippe Crine	COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	100%	3,402
JP 2012527244-A	2012-11-08		BioMarin Pharmaceutical Inc	Variants of C-Type Natriuretic Peptide	100%	1,176
US 20120316114-A1	2012-12-13	2012-05-08, priority 2009-05-20	Daniel J. Wendt	Variants of C-type Natriuretic Peptide	100%	1,176
US 8377884-B2	2013-02-19	2008-11-21, priority 2007-11-21	Biomarin Pharmaceutical Inc.	Variants of C-type natriuretic peptides	100%	672
WO 2013161895-A	2013-10-31		DAIICHISANKYO COMPANY LIMITED	An agent for promoting bone repairing	100%	98
US 8598121-B2	2013-12-03	2012-05-08, priority 2009-05-20	Biomarin Pharmaceutical Inc.	Variants of C-type natriuretic peptide	100%	1,176
US 20130323244-A1	2013-12-05	2013-05-21, priority 2012-05-21	Vanderbilt University	COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF	100%	3,388
JP 2014508510-A	2014-04-10	2011-12-23, priority 2011-08-16	ALEXION PHARMA INTERNATIONAL SARL	COMPOSITIONS COMPRISING NATRIURETIC PEPTIDES AND METHODS OF USE THEREOF	100%	3,402
JP 2015502336-A	2015-01-22	2012-10-18, priority 2012-05-21	ALEXION PHARMA HOLDING,VANDERBILT UNIVERSITY	COMPOSITIONS COMPRISING ALKALINE PHOSPHATASE AND/OR NATRIURETIC PEPTIDE AND METHODS OF USE THEREOF	100%	3,402

Top matches

The first 25 of 19,231 matches, in the order the results list them.

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
21,477	SEQ_ID_NO_7	AFN91539.1	WO 2009067639-A1	2009-05-28	100%	100%	100%	1.2e-23
1	SEQ_ID_NO_1	AFN91646.1	US 20100297021-A1	2010-11-25	100%	100%	100%	9.3e-23
2	SEQ_ID_NO_1	AFN91645.1	US 20100297021-A1	2010-11-25	100%	100%	100%	9.6e-23
3	SEQ_ID_NO_1	AFN91644.1	US 20100297021-A1	2010-11-25	100%	100%	100%	1.4e-22
3,554	SEQ_ID_NO_2	AFN91656.1	US 20100297021-A1	2010-11-25	100%	100%	100%	1.2e-23
7,042	SEQ_ID_NO_3	AFN91650.1	US 20100297021-A1	2010-11-25	100%	100%	100%	6.7e-24
10,545	SEQ_ID_NO_4	AFN91645.1	US 20100297021-A1	2010-11-25	100%	100%	100%	1.8e-23
14,170	SEQ_ID_NO_5	AFN91609.1	US 20100297021-A1	2010-11-25	100%	100%	100%	2.1e-24
14,173	SEQ_ID_NO_5	AFN91660.1	US 20100297021-A1	2010-11-25	100%	100%	100%	9.3e-24
17,830	SEQ_ID_NO_6	AFN91655.1	US 20100297021-A1	2010-11-25	100%	100%	100%	2.2e-24
21,478	SEQ_ID_NO_7	AFN91609.1	US 20100297021-A1	2010-11-25	100%	100%	100%	1.2e-23
21,479	SEQ_ID_NO_7	AFN91655.1	US 20100297021-A1	2010-11-25	100%	100%	100%	1.2e-23
21,493	SEQ_ID_NO_7	AFN91660.1	US 20100297021-A1	2010-11-25	100%	100%	100%	5.6e-23
14,171	SEQ_ID_NO_5	AOL49898.1	US 20120164142-A1	2012-06-28	100%	100%	100%	2.4e-24
21,480	SEQ_ID_NO_7	AOL49924.1	US 20120164142-A1	2012-06-28	100%	100%	100%	1.4e-23
21,481	SEQ_ID_NO_7	AOL49922.1	US 20120164142-A1	2012-06-28	100%	100%	100%	1.4e-23
21,482	SEQ_ID_NO_7	AOL49898.1	US 20120164142-A1	2012-06-28	100%	100%	100%	1.5e-23
21,483	SEQ_ID_NO_7	AOL49923.1	US 20120164142-A1	2012-06-28	100%	100%	100%	1.6e-23
21,484	SEQ_ID_NO_7	AOL49925.1	US 20120164142-A1	2012-06-28	100%	100%	100%	1.6e-23
14,172	SEQ_ID_NO_5	AOL50003.1	US 20120164142-A1	2012-06-28	98.6%	97.4%	100%	7.1e-24
21,485	SEQ_ID_NO_7	AOL50003.1	US 20120164142-A1	2012-06-28	98.6%	97.4%	100%	4.3e-23

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
21,486	SEQ_ID_NO_7	AOL49999.1	US 20120164142-A1	2012-06-28	98.6%	97.4%	100%	4.7e-23
21,487	SEQ_ID_NO_7	AOL49992.1	US 20120164142-A1	2012-06-28	98.6%	97.4%	100%	4.7e-23
21,488	SEQ_ID_NO_7	AOL49991.1	US 20120164142-A1	2012-06-28	98.6%	97.4%	100%	4.7e-23
21,489	SEQ_ID_NO_7	AOL49993.1	US 20120164142-A1	2012-06-28	98.6%	97.4%	100%	5.0e-23

Search 2: US 20260345734 A1: Use of C-type natriuretic peptide variants to treat skeletal dysplasia, plan 1 P2: SEQ ID NO: 1 to 7

Search ID	`db6bc4af-5bb0-4ff8-8a89-ae194bdc38e0`
In this case	Run from plan version 1, search P2, by ConductScience on 2026-11-24 00:15 UTC
Finished	2026-11-24 00:16 UTC
Data searched	Public sequences: UniProt 2026_04 and ENA ESTs: Swiss-Prot (487,796 sequences, 186,172,811 letters)
Data version	Snapshot 2026-11-10-37cac4ca8f21, set swissprot, sources to 2026-11-10, no additions
Engine	FASTA 36.3.8i; Sequences search engine 0.21.0
Settings	engine: Automatic; tool: ssearch36; program: blastp; query: protein
Plan filters	The tables below show matches with published before 2015-07-30, as the plan set
Query fingerprint	`e3b44e3c8578b2eee4b1a2c357d145ec5ab45e87a802ee00fa220c0b2880d52c`
Record fingerprint	`ad06723de1b2b3ee22a6ddedca130fa5d8eeaf78c85646cc3becfb44d318912d`

Smith-Waterman compares each query with every stored sequence. Each query returns up to 5,000 sequences, with the best alignment of each. FASTA36 fits its E-values to a sample of scores it draws the same way on every run, so the same search on the same snapshot returns the same rows. These results do not establish patentability.

Queries

Query	Length	Matches	Listed	Limit reached
SEQ_ID_NO_1	37		1,247	No
SEQ_ID_NO_2	38		1,150	No
SEQ_ID_NO_3	38		1,193	No
SEQ_ID_NO_4	38		1,437	No
SEQ_ID_NO_5	39		1,391	No
SEQ_ID_NO_6	39		1,374	No
SEQ_ID_NO_7	38		1,379	No

```
>SEQ_ID_NO_1  (37 letters)
      1  QEHPNARKYK GANKKGLSKG CFGLKLDRIG SNSGLGC

>SEQ_ID_NO_2  (38 letters)
      1  MQEHPNARKY KGANKKGLSK GCFGLKLDRI GSMSGLGC

>SEQ_ID_NO_3  (38 letters)
      1  PQEHPNARKY KGANKKGLSK GCFGLKLDRI GSMSGLGC

>SEQ_ID_NO_4  (38 letters)
      1  GQEHPNARKY KGANKKGLSK GCFGLKLDRI GSNSGLGC

>SEQ_ID_NO_5  (39 letters)
      1  PGQEHPNARK YKGANKKGLS KGCFGLKLDR IGSMSGLGC

>SEQ_ID_NO_6  (39 letters)
      1  MGQEHPNARK YKGANKKGLS KGCFGLKLDR IGSMSGLGC

>SEQ_ID_NO_7  (38 letters)
      1  GQEHPNARKY KGANKKGLSK GCFGLKLDRI GSMSGLGC
```

Top publications

No publication matched.

Top matches

The first 25 of 9,133 matches, in the order the results list them.

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
1,248	SEQ_ID_NO_2	P23582		1991	98.5%	97.4%	100%	4.1e-22
7,793	SEQ_ID_NO_7	P23582		1991	97.1%	100%	97.4%	9.1e-22
2,398	SEQ_ID_NO_3	P23582		1991	96.6%	100%	97.4%	9.7e-22
1	SEQ_ID_NO_1	P23582		1991	96%	97.3%	100%	7.8e-21
6,419	SEQ_ID_NO_6	P23582		1991	94.8%	100%	94.9%	1.0e-21
1,249	SEQ_ID_NO_2	P55207		1990	94.2%	92.1%	100%	8.7e-21
1,252	SEQ_ID_NO_2	P18104		1990	94.2%	92.1%	100%	8.7e-21
1,250	SEQ_ID_NO_2	P55206		1994	94.2%	92.1%	100%	8.7e-21
1,251	SEQ_ID_NO_2	Q61839		1994	94.2%	92.1%	100%	8.7e-21
1,253	SEQ_ID_NO_2	P56283		1998-07-15	94.2%	92.1%	100%	8.7e-21
5,028	SEQ_ID_NO_5	P23582		1991	93.9%	100%	94.9%	1.5e-21
3,591	SEQ_ID_NO_4	P23582		1991	93.3%	97.3%	97.4%	1.2e-20
7,795	SEQ_ID_NO_7	P55207		1990	92.8%	97.2%	94.7%	1.9e-20
7,798	SEQ_ID_NO_7	P18104		1990	92.8%	97.2%	94.7%	1.9e-20
7,794	SEQ_ID_NO_7	Q61839		1994	92.8%	97.2%	94.7%	1.9e-20
7,796	SEQ_ID_NO_7	P55206		1994	92.8%	97.2%	94.7%	1.9e-20
7,797	SEQ_ID_NO_7	P56283		1998-07-15	92.8%	97.2%	94.7%	1.9e-20
2,400	SEQ_ID_NO_3	P18104		1990	92.3%	97.2%	94.7%	2.0e-20
2,402	SEQ_ID_NO_3	P55207		1990	92.3%	97.2%	94.7%	2.0e-20

Row	Query	Match	Publication	First published	Query Match	Identity	Query coverage	E-value
2,399	SEQ_ID_NO_3	P55206		1994	92.3%	97.2%	94.7%	2.0e-20
2,401	SEQ_ID_NO_3	Q61839		1994	92.3%	97.2%	94.7%	2.0e-20
2,403	SEQ_ID_NO_3	P56283		1998-07-15	92.3%	97.2%	94.7%	2.0e-20
3	SEQ_ID_NO_1	P55207		1990	91.6%	94.4%	97.3%	1.6e-19
6	SEQ_ID_NO_1	P18104		1990	91.6%	94.4%	97.3%	1.6e-19
2	SEQ_ID_NO_1	P55206		1994	91.6%	94.4%	97.3%	1.6e-19

Case log

60 events; every event checks out. Each event's SHA-256 covers the event and the SHA-256 of the one before it, so a change to any event breaks the chain from there on. The table shows each SHA-256's first 12 characters, in the events' words too.

#	When (UTC)	By	Event	SHA-256
1	2026-11-24 00:15	ConductScience	Started the case “US 20260345734 A1: Use of C-type natriuretic peptide variants to treat skeletal dysplasia”.	`2ae5de3dc67e`
2	2026-11-24 00:15	ConductScience	Imported 35 claims from US 20260345734 A1 as set 1 (as published, 2026-11-05). Claims SHA-256 7548c2b76b74.	`b19f1f71ca9b`
3	2026-11-24 00:15	ConductScience	The rules (version 1.5.0) found 21 features.	`2161ea6df0fb`
4	2026-11-24 00:15	ConductScience	Read 155 paragraphs of the description from US 20260345734 A1, 3 citing a SEQ ID NO. Specification SHA-256 8d23e390728d.	`408d88a259b9`
5	2026-11-24 00:15	ConductScience	Set the application number to US 19/407,862, from US 20260345734 A1.	`51d9a07ced84`
6	2026-11-24 00:15	ConductScience	Set the prior art date to 2025-12-03 (filing date), from US 20260345734 A1.	`6ed0ab712ea5`
7	2026-11-24 00:15	ConductScience	Set the prior art date to 2015-07-30 (entered by hand).	`4f1d0e13feae`
8	2026-11-24 00:15	ConductScience	Accepted F1 in claim 1 (SEQ ID): “SEQ ID NO: 1”.	`f558404dcd42`
9	2026-11-24 00:15	ConductScience	Accepted F2 in claim 1 (SEQ ID): “SEQ ID NO: 2”.	`9c408737a6a2`
10	2026-11-24 00:15	ConductScience	Accepted F3 in claim 1 (SEQ ID): “SEQ ID NO: 3”.	`7a07984bf906`
11	2026-11-24 00:15	ConductScience	Accepted F4 in claim 1 (SEQ ID): “SEQ ID NO: 4”.	`40a5cd0fe9a9`
12	2026-11-24 00:15	ConductScience	Accepted F5 in claim 1 (SEQ ID): “SEQ ID NO: 5”.	`7d8edef37d73`
13	2026-11-24 00:15	ConductScience	Accepted F6 in claim 1 (SEQ ID): “SEQ ID NO: 6”.	`b01ef759bc30`
14	2026-11-24 00:15	ConductScience	Accepted F7 in claim 1 (SEQ ID): “SEQ ID NO: 7”.	`8d28c6a66fc8`
15	2026-11-24 00:15	ConductScience	Accepted F8 in claim 16 (SEQ ID): “SEQ ID NO: 1”.	`c4519322aca9`
16	2026-11-24 00:15	ConductScience	Accepted F9 in claim 16 (SEQ ID): “SEQ ID NO: 2”.	`355b5fdb5abb`
17	2026-11-24 00:15	ConductScience	Accepted F10 in claim 16 (SEQ ID): “SEQ ID NO: 3”.	`6d40edab9d3b`
18	2026-11-24 00:15	ConductScience	Accepted F11 in claim 16 (SEQ ID): “SEQ ID NO: 4”.	`3626e32b0047`
19	2026-11-24 00:15	ConductScience	Accepted F12 in claim 16 (SEQ ID): “SEQ ID NO: 5”.	`a6ef38cf410a`
20	2026-11-24 00:15	ConductScience	Accepted F13 in claim 16 (SEQ ID): “SEQ ID NO: 6”.	`1b46839fc917`
21	2026-11-24 00:15	ConductScience	Accepted F14 in claim 16 (SEQ ID): “SEQ ID NO: 7”.	`37dc227eab51`
22	2026-11-24 00:15	ConductScience	Accepted F15 in claim 23 (SEQ ID): “SEQ ID NO: 1”.	`73522a092afa`
23	2026-11-24 00:15	ConductScience	Accepted F16 in claim 23 (SEQ ID): “SEQ ID NO: 2”.	`0d27e69dada1`
24	2026-11-24 00:15	ConductScience	Accepted F17 in claim 23 (SEQ ID): “SEQ ID NO: 3”.	`c92939a14a37`
25	2026-11-24 00:15	ConductScience	Accepted F18 in claim 23 (SEQ ID): “SEQ ID NO: 4”.	`c58d99f9a2f9`
26	2026-11-24 00:15	ConductScience	Accepted F19 in claim 23 (SEQ ID): “SEQ ID NO: 5”.	`87355bb01d74`
27	2026-11-24 00:15	ConductScience	Accepted F20 in claim 23 (SEQ ID): “SEQ ID NO: 6”.	`0118789e90df`
28	2026-11-24 00:15	ConductScience	Accepted F21 in claim 23 (SEQ ID): “SEQ ID NO: 7”.	`bbb63d09516e`
29	2026-11-24 00:15	ConductScience	Drafted the plan: 2 searches, 0 features not covered.	`bb43a8611980`
30	2026-11-24 00:15	ConductScience	Locked plan version 1: 2 searches, 0 features not covered. Plan SHA-256 4b671f835c22.	`a298242d6643`

#	When (UTC)	By	Event	SHA-256
31	2026-11-24 00:15	ConductScience	Ran P1 and P2 from plan version 1: 2 search jobs.	`24dd6484512b`
32	2026-11-24 00:18	ConductScience	Chose 5 references for the chart of claim 1.	`fe9893331183`
33	2026-11-24 00:18	ConductScience	Chose 5 references for the chart of claim 16.	`19ed9af1a96c`
34	2026-11-24 00:18	ConductScience	Chose 5 references for the chart of claim 23.	`1c8c4ac4e1f9`
35	2026-11-24 00:18	ConductScience	Kept publication US 20100297021-A1 of search 48438060.	`9bc99069a707`
36	2026-11-24 00:18	ConductScience	Kept publication US 8198242-B2 of search 48438060.	`e53601dfb326`
37	2026-11-24 00:18	ConductScience	Kept publication US 20120164142-A1 of search 48438060.	`b17b08aadf68`
38	2026-11-24 00:18	ConductScience	Kept publication US 8598121-B2 of search 48438060.	`a56849354919`
39	2026-11-24 00:18	ConductScience	Kept publication US 20130323244-A1 of search 48438060.	`d2864ac0b92f`
40	2026-11-24 00:18	ConductScience	Accepted sentence 1 for publication US 20100297021-A1 of search 48438060: “SEQ ID NO: 145 of US 20100297021-A1 matches SEQ ID NO: 5 of claims 1, 16 and 23 at 100% identity over 39 of 39 residues (Query Match 100%).”	`77869aa9679e`
41	2026-11-24 00:18	ConductScience	Accepted sentence 3 for publication US 20100297021-A1 of search 48438060: “Published 2010-11-25, before the prior art date of 2015-07-30.”	`c11ce35c71f4`
42	2026-11-24 00:18	ConductScience	Accepted sentence 1 for publication US 8198242-B2 of search 48438060: “SEQ ID NO: 145 of US 8198242-B2 matches SEQ ID NO: 5 of claims 1, 16 and 23 at 100% identity over 39 of 39 residues (Query Match 100%).”	`2682149c12da`
43	2026-11-24 00:18	ConductScience	Accepted sentence 3 for publication US 8198242-B2 of search 48438060: “Published 2012-06-12, before the prior art date of 2015-07-30.”	`3a2e1811b001`
44	2026-11-24 00:18	ConductScience	Accepted sentence 1 for publication US 20120164142-A1 of search 48438060: “SEQ ID NO: 1047 of US 20120164142-A1 matches SEQ ID NO: 5 of claims 1, 16 and 23 at 100% identity over 39 of 39 residues (Query Match 100%).”	`3c1cc7e17259`
45	2026-11-24 00:18	ConductScience	Accepted sentence 3 for publication US 20120164142-A1 of search 48438060: “Published 2012-06-28, before the prior art date of 2015-07-30.”	`557d91b734f0`
46	2026-11-24 00:18	ConductScience	Accepted sentence 1 for publication US 8598121-B2 of search 48438060: “SEQ ID NO: 145 of US 8598121-B2 matches SEQ ID NO: 5 of claims 1, 16 and 23 at 100% identity over 39 of 39 residues (Query Match 100%).”	`4d604cdf930b`
47	2026-11-24 00:18	ConductScience	Accepted sentence 3 for publication US 8598121-B2 of search 48438060: “Published 2013-12-03, before the prior art date of 2015-07-30.”	`cda744c542a8`
48	2026-11-24 00:18	ConductScience	Accepted sentence 1 for publication US 20130323244-A1 of search 48438060: “SEQ ID NO: 1047 of US 20130323244-A1 matches SEQ ID NO: 5 of claims 1, 16 and 23 at 100% identity over 39 of 39 residues (Query Match 100%).”	`d24f986e19db`
49	2026-11-24 00:18	ConductScience	Accepted sentence 3 for publication US 20130323244-A1 of search 48438060: “Published 2013-12-05, before the prior art date of 2015-07-30.”	`0ef52d7322ee`
50	2026-11-24 00:18	ConductScience	Accepted the summary of the case, filled in from template conductbiology.summaries.template.case.v1 b65b47e0.	`658150970d35`
51	2026-11-24 00:18	ConductScience	Accepted the summary of the results, filled in from template conductbiology.summaries.template.results.v1 91ed1f45.	`5dcd86ca9eb9`

#	When (UTC)	By	Event	SHA-256
52	2026-11-24 00:18	ConductScience	Accepted the summary of search 1, filled in from template conductbiology.summaries.template.search.v1 6781e001.	`8d20116f02ba`
53	2026-11-24 00:18	ConductScience	Accepted the summary of search 2, filled in from template conductbiology.summaries.template.search.v1 6781e001.	`7550cf5a825d`
54	2026-11-24 00:18	ConductScience	Accepted the summary of SEQ ID NO: 1, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`a1efc93bbd7a`
55	2026-11-24 00:18	ConductScience	Accepted the summary of SEQ ID NO: 2, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`42fc462afefa`
56	2026-11-24 00:18	ConductScience	Accepted the summary of SEQ ID NO: 3, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`9724914c90e2`
57	2026-11-24 00:18	ConductScience	Accepted the summary of SEQ ID NO: 4, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`690398976733`
58	2026-11-24 00:18	ConductScience	Accepted the summary of SEQ ID NO: 5, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`84dfc36082ef`
59	2026-11-24 00:18	ConductScience	Accepted the summary of SEQ ID NO: 6, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`8807b1b0fcd9`
60	2026-11-24 00:18	ConductScience	Accepted the summary of SEQ ID NO: 7, filled in from template conductbiology.summaries.template.seqid.v1 8b59a799.	`0b439b3ae45e`